AACR to Partner with the Bristol Myers Squibb Foundation on its Diversity in Clinical Trials Career Development Program
Letters of Intent to participate in the program and related workshop due May 28 PHILADELPHIA – Today, the American...
Search/Filter
Loading...
AACR Congratulates Newest Members of the National Academy of Sciences
Among those recognized are seven members of the AACR PHILADELPHIA — The American Association for Cancer Research (AACR) congratulates...
American Association for Cancer Research Recognizes New 2020-2021 Research Grantees
PHILADELPHIA — The American Association for Cancer Research (AACR) is proud to announce its newest class of grant recipients....
AACR Applauds Biden Administration for its Plan to Protect the Public from the Dangers of Menthol Cigarettes and Flavored Cigars
The announcement was in response to a 2013 citizen petition that outlined the science and called for a ban...
Average-risk Individuals May Prefer Stool-based Tests Over Colonoscopy for Colorectal Cancer Screening
PHILADELPHIA – When given a choice, most individuals with an average risk of colorectal cancer said they would prefer...
John D. Carpten, PhD, FAACR, to Join the AACR Board of Directors
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced that John D. Carpten, PhD, FAACR, has been...
American Association for Cancer Research Inaugurates New Leadership at Virtual AACR Annual Business Meeting of Members 2021
David A. Tuveson, MD, PhD, FAACR, inaugurated as President PHILADELPHIA — The American Association for Cancer Research (AACR) welcomes...
Healthy Lifestyle May Offset Risk of Lethal Prostate Cancer in Men With High Genetic Risk
PHILADELPHIA – Men who had a high genetic risk of developing prostate cancer were less likely to develop a...
Copanlisib-Rituximab Combination Cuts Lymphoma Progression or Death by Nearly Half in CHRONOS-3 Trial
PHILADELPHIA – A combination of copanlisib (Aliqopa) and rituximab led to a 48 percent reduction in the risk of...
Immunotherapy Response Prediction Using Tumor Mutational Burden May Differ Between Men and Women With Melanoma
PHILADELPHIA – Tumor mutational burden (TMB) was an accurate predictor of response to treatment with immune checkpoint inhibitors for...